Biocept Appoints Philippe Marchand as Chief Operating Officer
Industry veteran to oversee operations for the company and its CNSide™ cerebrospinal fluid assay to aid in the management of patients with metastatic brain cancers
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Philippe Marchand, Ph.D., to the position of Chief Operating Officer, effective today. Dr. Marchand will be responsible for advancing the company’s strategic and operational objectives, including all laboratory operations of its CNSide cerebrospinal fluid assay, which helps physicians better detect and manage treatment of patients with metastatic cancers involving the central nervous system.
“Biocept is excited to welcome an executive of Philippe’s caliber to our team as we work to establish CNSide as the standard-of-care diagnostic test for patients with metastatic cancers involving the brain or spinal cord,” said Sam Riccitelli, Biocept’s Chairman, and Interim President and CEO. “He shares our strong belief that having a quantitative method to analyze tumor cells in the cerebrospinal fluid will be key to improving care for these patients.”
Dr. Marchand is a veteran biotechnology executive and scientist with a proven track record in transitioning concepts to implementation and commercialization. Most recently, Dr. Marchand was the Chief Operating Officer of Biosplice Therapeutics, aiding in the development of first-in-class small-molecule therapeutics. Previously, he was the Chief Information Officer of Genoptix, where he oversaw the creation of the company’s diagnostics laboratory, and was instrumental in its IPO and subsequent acquisition by Novartis. Following the acquisition, he assumed responsibilities for global IT operations for Novartis Oncology.
“As the medical community develops new targeted therapies for metastatic brain cancers, it is imperative to have more sophisticated diagnostic tests available to characterize tumor cells in the cerebrospinal fluid, identify treatment targets, and monitor response to therapy,” Dr. Marchand said. “I am impressed with the enormous progress Biocept has made in the development and commercialization of CNSide, and look forward to helping take the company and assay to the next level for the benefit of patients and physicians.”
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to the ability of CNSide to impact life expectancy and quality of life, our ability to establish CNSide as the new standard of care for the diagnosis of patients with suspected cancer metastasis to the CNS, our ability to expand our CSF testing menu for additional tumor types and biomarkers in the future, and our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at http://www.sec.gov/.
Andrea Sampson, Sampson PR Group
Jody Cain, LHA Investor Relations